A novel bispecific antibody (BCG020) targeting both epidermal growth factor receptor (EGFR) and CD70 was developed to overcome resistance to EGFR-targeted therapies. BCG020 demonstrated high affinity to both EGFR and CD70, superior internalization activity, and potent inhibition of tumor growth in xenograft models. These findings suggest that BCG020 holds promise as a treatment for solid tumors with high expression of both EGFR and CD70.
